Posted by Michael Wonder on 14 May 2021
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
14 May 2021 - NICE recommends pembrolizumab for colorectal cancer patients with rare mutations.
A potentially life-extending treatment for some people with untreated metastatic colorectal cancer, who have specific mutations in their cancer cells, has been approved for routine commissioning by NICE in draft guidance published today.
The draft guidance recommends pembrolizumab (Keytruda, Merck Sharp & Dohme) for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency.
